Followers | 247 |
Posts | 49942 |
Boards Moderated | 51 |
Alias Born | 08/29/2007 |
Monday, July 03, 2023 2:42:57 PM
A Novel Gene Therapy Promises Relief For A Rare Genetic Skin Disorder
ARK Invest_Illustration_Pierce Jamieson_Final_Circle 400 px By Pierce Jamieson | @PierceARK
Research Associate
Recently, the US Food and Drug Administration (FDA) approved Krysta Biotech’s (KRYS) groundbreaking advance1 in gene therapy, Vyjuvek, to treat wounds in patients suffering from dystrophic epidermolysis bullosa (DEB), a rare and serious genetic skin disorder caused by mutations in the collagen Type VII alpha 1 chain (COL7A1) gene. As the first FDA-approved gene therapy for DEB, Vyjuvek is a significant breakthrough.
Vyjuvek uses a genetically modified HSV-1 to deliver normal copies of the COL7A1 gene to wounds, restoring the integrity of the skin with fibrils that hold skin layers together. Treated with Vyjuvek, 65% of wounds closed completely.
I am writing a book, American Cars of 1958. Check often for the latest addition. https://investorshub.advfn.com/American-Cars-of-1958-37252/
Recent KRYS News
- Krystal Biotech to Present at BofA Securities 2024 Health Care Conference • GlobeNewswire Inc. • 05/08/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2024 12:17:38 PM
- Index Futures Point to Strong Monday Opening, Building on Last Week’s Gains; Oil Prices Rise • IH Market News • 05/06/2024 12:09:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 12:04:25 PM
- Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024 • GlobeNewswire Inc. • 04/26/2024 11:00:00 AM
- Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung • GlobeNewswire Inc. • 04/22/2024 11:00:00 AM
- Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting • GlobeNewswire Inc. • 04/04/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2024 01:20:02 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2024 01:16:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 02:33:56 AM
- Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/28/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/26/2024 06:35:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 01:04:28 PM
- Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/26/2024 12:59:55 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2024 12:49:58 PM
- U.S. Index Futures Dip Amid Inflation Data Anticipation, Oil and Iron Ore Prices Retreat • IH Market News • 02/26/2024 10:57:28 AM
- Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024 • GlobeNewswire Inc. • 02/20/2024 12:00:00 PM
- Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung • GlobeNewswire Inc. • 02/13/2024 12:00:00 PM
- Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference • GlobeNewswire Inc. • 02/01/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 10:44:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/22/2024 04:43:50 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM